290 results on '"Makatsoris, Thomas"'
Search Results
2. Exploring the Dynamics of B Cell Subpopulations in Response to Immune Checkpoint Inhibitors: A Prospective Study
3. Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness
4. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
5. Small Extracellular Vesicles (sEVs) Biogenesis Molecular Players Are Associated with Clinical Outcome of Colorectal Cancer Patients
6. Expression Of Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients
7. The Role of Chemotherapy in the Treatment of Bone Metastases
8. Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG)
9. Abstract 1966: Dr
10. Prognostic value of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with combination of immunotherapy with chemotherapy: Preliminary results from a European retrospective study.
11. Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression
12. Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
13. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
14. RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
15. Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients
16. Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort
17. Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.
18. AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study
19. Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: A Hellenic Cooperative Oncology Group (HeCOG) phase II study
20. A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
21. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)
22. Two Cycles of Etoposide/Cisplatin Cured All Patients with Stage I Testicular Seminoma: Risk-Adapted Protocol of the Hellenic Cooperative Oncology Group
23. Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: A hellenic cooperative oncology group phase II study
24. Induction Chemotherapy with Cisplatin, Epirubicin, and Paclitaxel (CEP), Followed by Concomitant Radiotherapy and Weekly Paclitaxel for the Management of Locally Advanced Nasopharyngeal Carcinoma: A Hellenic Cooperative Oncology Group Phase II Study*
25. A phase II study of capecitabine plus oxaliplatin (XELOX): A new first-line option in metastatic colorectal cancer
26. NF-κB2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development
27. The Potential Role of TGFβ1, TGFβ2 and TGFβ3 Protein Expression in Colorectal Carcinomas: Correlation with ClassicHistopathologic Factors and Patient Survival
28. The Role of Chemotherapy in the Treatment of Bone Metastases
29. Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report
30. PIOS ratio: predicting the best response of non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.
31. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
32. Differentially Methylated Ultra-Conserved Regions Uc160 and Uc283 in Adenomas and Adenocarcinomas Are Associated with Overall Survival of Colorectal Cancer Patients
33. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
34. Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
35. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab
36. The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab
37. The Potential Role of Bcl-2 and Protein Expression in Hepatocellular Carcinomas: A Clinicopathologic Study
38. Authors and Coauthors of Volume 3
39. Effect of epoetin alfa on hemoglobin and quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial
40. Temozolomide (TMZ) combined with cisplatin (CDDP) for brain metastases from solid tumors: A Hellenic Cooperative Oncology Group phase II study
41. TGFβ1, p21WAF1 and Ki67 expression in colorectal carcinomas. Biologic and prognostic implications
42. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study
43. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
44. An MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations myofasciitis is the prominent imaging finding
45. Abstract 1343: SNPs in the NFKB alternative pathway genesCD40, BAFFRandLTβRin CRC
46. OP0335 A PROSPECTIVE CLINICAL AND MRI STUDY OF IMMUNE CHECKPOINT INHIBITOR (ICI)-INDUCED MUSCULOSKELETAL MANIFESTATIONS MYO-FASCIITIS AND NOT SYNOVITIS IS THE PROMINENT IMAGING FINDING
47. Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients
48. Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO).
49. Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC.
50. Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.